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Abstract
Background: Burkitt lymphoma, a childhood cancer common in parts of sub-Saharan Africa, has been associated with
Epstein Barr Virus (EBV) and malaria, but its association with human immunodeficiency virus (HIV) is not clear.
Methodology/Principal Findings: We conducted a case-control study of Burkitt lymphoma among children (aged #15
years) admitted to the pediatric oncology unit in Blantyre, Malawi between July 2005 and July 2006. Cases were 148 children
diagnosed with Burkitt lymphoma and controls were 104 children admitted with non-malignant conditions or cancers other
than hematological malignancies and Kaposi sarcoma. Interviews were conducted and serological samples tested for
antibodies against HIV, EBV and malaria. Odds ratios for Burkitt lymphoma were estimated using unconditional logistic
regression adjusting for sex, age, and residential district. Cases had a mean age of 7.1 years and 60% were male. Cases were
more likely than controls to be HIV positive (Odds ratio (OR)) = 12.4, 95% Confidence Interval (CI) 1.3 to 116.2, p= 0.03). ORs
for Burkitt lymphoma increased with increasing antibody titers against EBV (p= 0.001) and malaria (p= 0.01). Among HIV
negative participants, cases were thirteen times more likely than controls to have raised levels of both EBV and malaria
antibodies (OR= 13.2; 95% CI 3.8 to 46.6; p= 0.001). Reported use of mosquito nets was associated with a lower risk of
Burkitt lymphoma (OR= 0.2, 95% CI, 0.03 to 0.9, p= 0.04).
Conclusions: Our findings support prior evidence that EBV and malaria act jointly in the pathogenesis of Burkitt lymphoma,
suggesting that malaria prevention may decrease the risk of Burkitt lymphoma. HIV may also play a role in the etiology of
this childhood tumor.
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Introduction
Endemic Burkitt lymphoma is a common childhood cancer in
parts of sub-Saharan Africa, including Malawi [1,2] with a male
preponderance and peak age of tumor occurrence at 7 years [3,4].
Jaw tumors, usually involving multiple quadrants, are a charac-
teristic feature, especially in younger children [5]. Two infectious
agents, EBV and Plasmodium falciparum malaria have been
associated with the etiology of Burkitt lymphoma. At least 90%
of endemic Burkitt lymphoma cases are thought to be EBV-
associated [6,7], with supportive evidence including the presence
of EBV-DNA clonally integrated into tumor tissue and sero-
epidemiological associations with EBV antibodies [7–9]. Ecolog-
ical studies demonstrating a positive association between Burkitt
lymphoma and malaria [10–12] have only recently been
supported by a case-control study in Uganda [13]. Malaria is
the leading cause of death in children under 5 years of age in
Malawi. Sixty-eighty percent of infants living alongside Lake
Malawi were found to be infected with Plasmodium falciparum by the
age of 10 months [14]. Children under the age of five years had
suffered an average of nine clinical episodes of malaria illness per
year and many remain chronically parasitaemic year-round [14].
Use of insecticide-treated nets is one of the main objectives for the
Roll Back Malaria campaign in Malawi and other malaria-
endemic countries [15].
Epidemiological evidence for an association between HIV and
endemic Burkitt lymphoma is more uncertain [16,17]. While one
case-control study from Uganda reported a positive association
with HIV infection [18]; a small subset of preliminary data from
this study reported no association [19]. Associations with socio-
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economic and environmental factors have also been suggested but
relatively little studied [5,20]. Here, we report risk factors for
childhood Burkitt lymphoma from a case-control study conducted
in Malawi focusing particular attention on three infections: HIV,
EBV and malaria.
Materials and Methods
This case-control study was nested within a larger study of
childhood cancer conducted at the main hospital in Blantyre,
Malawi, between July 2005 and July 2006. All 305 children aged
15 years or younger with a provisional diagnosis of cancer
admitted to the pediatric oncology ward in Blantyre were recruited
into the larger study. Preliminary clinical diagnoses of cancer were
made by one investigator (EM) and were confirmed by histology,
cytology or other laboratory investigations where possible. The
study included 148 cases, 109 (75%) of whom were histologically
diagnosed with Burkitt lymphoma, and 104 controls, 73 (74%) of
whom were histologically diagnosed with other conditions
(Figure 1). Just over half (n = 83) of children with Burkitt
lymphoma presented with jaw lesions, although abdominal lesions
were also relatively frequent (n = 57). Controls included 93
children diagnosed with cancer: Wilms tumor (n = 30), retinoblas-
toma (n= 18), rhabdomyosarcoma (n= 18), non-malignant (non-
infectious) conditions (n = 11), neuroblastoma (n= 6), hepatocellu-
lar carcinoma (n= 4), malignant teratoma (n= 4), bone tumor
(n = 4), ovarian tumor (n= 3), and one of six other tumor types/
sites (abdominal, brain, hepatoblastoma, soft tissue tumor,
squamous cell carcinoma and yolk sac tumor). A further 11
controls were children with non-malignant conditions, admitted to
the oncology ward with a provisional diagnosis of cancer, who
were subsequently found to have non-malignant conditions
(aplastic anaemia, benign cystic teratoma, benign mesenchymal
tumor, cellular mesoblastic nephroma, chronic inflammation,
Down’s syndrome, hemangioma, liver abscess, melanotic neuro-
ectodermal tumor of infancy, ranula). All children diagnosed with
hematological cancers (including leukemia, non-Burkitt lympho-
ma, and small round blue cell tumors) and Kaposi’s sarcoma were
excluded from the control group, because of possible diagnostic
overlap and previously known associations with HIV.
Recruitment and data collection
Five local nurses were employed and trained to recruit children
and their mothers into the study and to administer standardized
questionnaires. The parent or guardian of each child was
approached and invited to participate in the study and provide
written informed consent for their child to be included in the
study. All children seen in the pediatric oncology ward with
suspected cancer were routinely tested for HIV infection. The
mother of each child was also asked to consent to be interviewed
and also provided a serologic sample for testing for antibodies
against HIV, EBV, malaria and syphilis. Appropriately trained
staff provided pre- and post-HIV test counseling. Mothers of 102
(69%) cases and of 80 (77%) controls consented and were
interviewed about demographic and socio-economic factors, their
child’s birth, household characteristics and their own sexual and
reproductive histories. Ethical approval for the study was obtained
from the Oxford Tropical Research Ethics Committee and the
Malawian College of Medicine Research and Ethics Committee.
Figure 1. Burkitt lymphoma cases and controls recruitment flow chart.
doi:10.1371/journal.pone.0002505.g001
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Laboratory procedures
HIV serostatus was determined on site for 146 cases (99%) and 93
controls (90%) and also for 97 (95%) mothers of cases and 75 (94%)
mothers of controls using Determine HIV (Abbott Laboratories,
Illinois, USA) as a screening test and Uni-GoldTM HIV (Trinity
Biotech PLC, Ireland) as a confirmatory test, as used in other studies
from Malawi [16,21]. Serological testing for IgG viral capsid antigen
EBV antibodies was performed for 138 (93%) cases, 95 (91%)
controls, 100 (98%) mothers of cases and for 77 (96%) mothers of
controls, at the Wolfson Institute for Biomedical Research based at
University College, London using indirect immunofluorescence (IFA)
[22]. This well validated serological test has been used elsewhere [23].
For the purposes of this analysis, children were categorized into one of
three EBV antibody groups: low (antibodies levels of 1:640 or less),
medium (antibodies levels of 1:1280 to 1:2560), and high (antibody
levels of 1:5120 to 1:20480). Because the number of mothers was
smaller, they were categorized into two EBV antibody groups: low
(antibody levels of 1:640 or less) and medium/high (antibody levels of
1:1280 to 1:20480). Antibodies against Plasmodium falciparum were
measured for 139 (94%) cases and 96 (92%) controls and also for 100
(98%) mothers of cases and 77 (96%) mothers of controls, at the
Centre for Clinical Vaccinology and Tropical Medicine in Oxford
using an Enzyme-linked ImmunoSorbent Assay (ELISA) [24]. The
technique used a Plasmodium falciparum schizont extract (PfSE) as the
malaria antigen, which has been used elsewhere [25]. Using optical
density (OD) readings as a surrogate measure of malaria antibody
titers, children were categorized as either negative/low (OD,0.2), or
medium/high (OD$0.2) and mothers as either low (OD,1) or
medium/high (OD$1).
In addition, syphilis tests were conducted in Malawi, for 99 (97%)
mothers of cases and for 77 (96%) mothers of controls, using the
Rapid Plasma Reagin (RPR) test (Abbot Determine, Alloa, Scotland)
and, if positive, confirmed by the Treponema pallidum hemaglutination
assay (TPHA) (Biotech TPHA kit, Biotech Laboratories Ltd, Suffolk,
UK). Both syphilis tests were conducted according to the manufac-
turer’s instructions. Women were defined as having current or prior
syphilis infection if they had positive RPR and TPHA tests.
Statistical analyses
Data were entered into an Access database in Malawi [26] and
analyses were performed in Oxford using STATA computer
software (version 9) [27]. Odds ratios (ORs) were estimated by
maximum likelihood using unconditional logistic regression. All
ORs relating to data on children were adjusted for child’s age (under
5 years, and 5 years and over), sex and residence (rural, urban),
while those relating to data on mothers were adjusted for mother’s
age (under 30 years, 30 years and over) and residence. Analyses
examining associations with EBV and malaria were restricted to
HIV negative cases and controls to exclude possible confounding
effects of HIV on these antibody titers. All p values reported were
obtained using two-sided tests of statistical significance.
To establish an index of poverty, data on eight proxy markers
were combined (ownership of a phone, television, fridge, radio,
chickens, and availability of piped water, ownership of land and
electricity in the home). Individuals were assigned to one of two
groups: those ‘better off’, and those ‘worse off’. The ‘better off’
group were those having either a television, fridge, phone,
electricity or piped water, in addition to one or more of the other
three markers listed above, while the ‘worse off’ group did not
posses any of these five items).
Results
General characteristics
Sixty percent of all 148 cases were boys and their ages ranged
from 2 years to 15 years (mean age= 7.1 (standard deviation (SD)
2.6 years). Controls were younger (mean age = 5.1 (SD 3.9 years)
and included a slightly smaller percentage of boys (55%) (Table 1).
Almost 80% (n= 111) of cases and 70% (n= 69) of controls were
reported to reside in rural areas and the percentage living in
‘‘better off’’ households was lower among cases (38% versus 49%).
Only four cases and one control reported having a mother who
had died. Comparison of characteristics of the 135 HIV negative
cases and 90 HIV negative controls showed similar patterns
(Table 1).
Table 1. Characteristics of children diagnosed with Burkitt lymphoma (cases) and their controls.
CHARACTERISTIC All children HIV negative children
Cases (n=148) Controls (n=104) Cases (n=137) Controls (n=91)
1Age (years) Median (IQR) 7 (5 to 9) 4 (2 to 8) 7 (5 to 9) 4 (2 to 7)
Mean (SD) 7.1 (2.6) 5.1 (3.9) 7.2 (2.6) 5.1 (3.8)
Age groups 0 to 4 19 (13%) 57 (55%) 15 (11%) 49 (54%)
5 to 15 126 (87%) 46 (45%) 120 (89%) 41 (46%)
Sex Male 89 (60%) 57 (55%) 81 (59%) 53 (58%)
Female 59 (40%) 47 (45%) 56 (41%) 38 (42%)
1Residence Rural 111 (78%) 69 (70%) 104 (79%) 66 (74%)
Urban 32 (22%) 30 (30%) 28 (21%) 23 (26%)
2Markers of poverty Worse off 63 (62%) 41 (51%) 99 (72%) 57 (63%)
Better off 39 (38%) 39 (49%) 38 (28%) 34 (37%)
1Child birth order Less than four 100 (68% 66 (65%) 91 (67%) 58 (65%)
Four or higher 46 (32%) 36 (35%) 44 (33%) 31 (35%)
1Mother alive Yes 144 (97%) 103 (99%) 135 (99%) 90 (99%)
No 4 (3%) 1 (1%) 2 (1%) 1 (1%)
1Numbers may not add to the total because of missing values.
2See methods.
doi:10.1371/journal.pone.0002505.t001
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HIV, EBV and malaria
The percentage of HIV positive children was small for both
cases and controls (6% (n= 9) for cases and 2% (n= 2) for
controls). However, after adjustment for child’s age, sex and
residence, cases were 12 times more likely than controls to be HIV
positive (OR=12.4, 95% CI 1.3 to 116.2, p=0.03) (Table 2).
When analyses were restricted to cases (n = 109) and controls
(n = 65) whose diagnoses were histologically verified, cases were
still almost 10 times more likely than controls to be HIV positive
(OR=9.7, 95% CI 1 to 95.7, p=0.02).
Sixty percent (n = 77) of HIV negative cases and 21% (n= 19)
of HIV negative controls had high EBV antibody levels. ORs
for developing Burkitt lymphoma were strongly associated with
increasing titers of antibodies against EBV antigens, increasing
from 4.1 for those with medium levels, to 14.8 for those with
high levels, as compared to those with the lowest levels
(ptrend,0.001) (Table 2). Seventy-one percent (n = 91) of HIV
negative cases had medium/high levels of malaria antibodies
compared to 47% (n= 42) of HIV negative controls. The
adjusted OR for developing Burkitt lymphoma was 2.4 for those
whose antibodies against malaria were medium to high
compared to those whose antibodies were negative or low
(p=0.01) (Table 2).
The joint effects of EBV and malaria antibodies were examined
by estimating adjusted ORs for children with raised levels of EBV
antibodies only, raised levels of malaria antibodies only, and raised
levels of both EBV and malaria antibodies, compared with
children with low levels of both (Table 3). ORs were 1.4 for
children with raised EBV antibody titers only and 5.7 for those
with raised malaria antibody titers only, while the OR for children
with high levels of both EBV and malaria antibodies was estimated
to be 13.2 (95% CI 3.8 to 46.6, p,0.001). Although the data were
limited, there was no difference in EBV and malaria antibody
levels between HIV negative and positive Burkitt lymphoma cases
(data not shown).
Mosquito net use
Questions regarding household mosquito net ownership and
use, were introduced eight months after the study began and were,
therefore, only available for 30 (20%) of Burkitt lymphoma cases
and 25 (24%) of controls (Table 4). Eighty percent (n = 20) of
control households and 60% (n= 18) of Burkitt lymphoma
households reported owning mosquito nets (OR=0.2, 95% CI
0.03 to 1.2, p=0.08), while 79% (n= 20) of controls and 57%
(n= 17) of cases reported having used them (OR=0.2, 95% CI
0.03 to 0.9, p=0.04).
Maternal characteristics
Characteristics of 80 HIV negative cases and controls are shown
in Table 5. OR estimates for Burkitt lymphoma were almost 5 fold
Table 2. Association between antibodies against HIV, EBV and malaria, in relation to risk of Burkitt lymphoma.
RISK FACTOR Prevalence Number
1Adjusted OR (95% CI)
x2 for heterogeneity
ALL CHILDREN
Cases Controls Cases Controls
*Child HIV status Positive 6% 2% 9 2 12.4 (1.3 to 116.2)
Negative 94% 98% 137 91 1.0
x2 (1df) = 7.2 p= 0.03
HIV NEGATIVE ONLY
*2EBV antibodies Low 9% 43% 12 38 1.0
Medium 31% 36% 39 32 4.1 (1.6 to 10.1)
High 60% 21% 77 19 14.8 (5.8 to 38.5)
x2 (1df) = 37.8 ptrend,0.001
*3Malaria antibodies Negative/Low 29% 53% 38 48 1.0
Medium/High 71% 47% 91 42 2.4 (1.2 to 4.4)
x2 (1df) = 6.9 p,0.01
1Adjusted for child age, sex and residence.
2EBV antibody categories: Low (#1:640), Medium (1:1280 to 1:2560), High (1:5120 to 1:20480).
3Malaria antibody categories: Negative/low (OD,0.2), Medium/high (OD$0.2).
*Data missing.
doi:10.1371/journal.pone.0002505.t002
Table 3. Joint effects of serological results for EBV and
malaria in HIV negative cases and controls
Cases/Controls
(126/89)
1Adjusted OR
(95% CI)
2EBV
antibodies
3Malaria
antibodies
Low Negative/Low 5/22 1.0
Medium/High 7/16 1.4 (0.3 to 6.3)
Medium/
High
Negative/Low 32/25 5.7 (1.6 to 20.7)
Medium/High 82/26 13.2 (3.8 to 46.6)
x2 (1df) = 31
p,0.001
1Adjusted for child age, sex and residence
2EBV antibody categories: Low (#1:640), Medium/High ($1:1280)
3Malaria antibody categories: Negative/low (OD,0.2), Medium/high (OD$0.2)
doi:10.1371/journal.pone.0002505.t003
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higher for children who had more than 3 siblings alive than those
with up to 3 siblings alive (OR=4.5, 95% CI 1.4 to 14.1, p=0.01).
Although not statistically significant, 19% (n= 15) of mothers of
cases and 7% (n= 4) of mothers of controls reported having
children with different biological fathers (OR=2.5, 95% CI 0.8 to
8.5, p=0.1). The OR was raised for children whose mothers
reported more than 1 lifetime sexual partner (adjusted OR=3.0,
95% CI 1.2 to 7.6, p=0.02). Seventy-nine percent (n = 65) of case
mothers and 70% (n= 40) of control mothers had high EBV
antibody titers (OR= 2.1, 95% CI 0.8 to 5.7, p=0.1). Maternal
syphilis status and level of malaria antibodies were not associated
with Burkitt lymphoma in the child.
Discussion
This case-control study of childhood Burkitt lymphoma in
Malawi has focused on the potential role played by three different
infectious diseases in children: HIV, EBV and malaria. The
positive association between Burkitt lymphoma and HIV found
here is similar to that reported from a recent study conducted in
Uganda [18]. Most other reports addressing this issue in African
children have been case series or based on routinely collected data
and have not been able to adjust for important confounding
factors such as child’s age, sex and residence [16]. HIV may be
acting as an indirect co-factor in the etiology of Burkitt lymphoma
by reducing the effectiveness of T cell based immune response to
oncogenic viruses [28] or by reducing the EBV-specific T cell
function, leading to proliferation of EBV infected B cells and
eventual tumor formation [29]. These findings suggest that
reducing HIV incidence, or treatment of HIV with antiretroviral
drugs, may lead to a reduction in the incidence of Burkitt
lymphoma in children. However, the number of HIV positive
cases of Burkitt lymphoma reported to date is relatively small and
considerable uncertainty therefore remains about the magnitude
of association between HIV and Burkitt lymphoma among African
children.
In accordance with results from previous epidemiological studies
from sub-Saharan Africa, we have clear evidence to suggest that the
risk of Burkitt lymphoma increases with increasing titers of
antibodies against EBV in the child [7,9,13]. Because Burkitt
lymphoma is a systemic disease and because we have used a case-
control design it is possible that the raised antibody titers against
EBV were a result of the tumor rather than the cause of the disease
(reverse causality). Nevertheless, the results of our case-control study
are similar to those from a prospective investigation [7,9].
In contrast, previous evidence for an association between
Burkitt lymphoma and malaria has been largely ecological [30–
32]. This case-control study also provides more direct evidence of
an association between malaria antibodies in the child and risk of
Burkitt lymphoma comparable to those recently reported from a
similar study in Uganda [13]. While anti-malarial antibodies are
not thought to reflect current infection, but rather previous
exposure, uncertainty still remains about the longevity of these
antibodies post-infection [33–36].
There is clear evidence from clinical trials that use of bed nets
reduces mortality from malaria among children [37,38] and our
findings raise the possibility that this preventive measure against
malaria may have potential to decrease the risk of Burkitt
lymphoma in African children. Reported use of household
insecticides and mosquito nets were associated with a lower risk
Table 4. Use of mosquito nets in Burkitt lymphoma cases and
controls.
RISK FACTOR Cases Controls
1Adjusted OR
(95% CI)
n =30 n=25 x2 for heterogeneity
ALL CHILDREN
2Home mosquito nets ownership
Yes 18 20 0.2 (0.03 to 1.2)
No 12 5 1.0
x2 (1df) = 3.7 p= 0.08
2Child use mosquito net?
Yes 17 20 0.2 (0.03 to 0.9)
No 12 5 1.0
x2 (1df) = 5.0 p= 0.04
1Adjusted for child age, sex and residence.
2Numbers reduced towards end of study because questions introduced later.
doi:10.1371/journal.pone.0002505.t004
Table 5. Odds ratio estimates for maternal sexual and
reproductive factors and serological test results, restricted to
HIV negative mothers.
RISK FACTOR Cases/Controls
1Adjusted OR (95%CI)
x2for heterogeneity
HIV NEGATIVE MOTHERS OF HIV NEGATIVE CHILDREN
INTERVIEWS
Number of children alive
Less than four 26/30 1.0
Four or more 54/26 4.5 (1.4 to 14.1)
x2 (1df) = 7.4 p= 0.01
Children with different fathers
No 65/53 1.0
Yes 15/4 2.5 (0.8 to 8.5)
x2 (1df) = 2.2 p= 0.1
Reported number of sexual partners
Less than two 37/39 1.0
Two or more 38/15 3.0 (1.2 to 7.6)
x2 (1df) = 5.8 p= 0.02
SEROLOGICAL TESTS
2Mother malaria antibodies
Low 32/28 1.0
High 50/29 1.2 (0.5 to 2.7)
x2 (1df) = 0.2 p= 0.6
3Mother EBV
Low 17/17 1.0
Medium/High 65/40 2.1 (0.8 to 5.7)
x2 (1df) = 2.3 p= 0.1
Syphilis
Negative 71/52 1.0
Positive 11/6 1.2 (0.4 to 3.8)
x2 (1df) = 0.1 p= 0.8
1Adjusted for mother age and residence.
2Mother malaria antibody categories: Low (OD,1), Medium/high (OD$1).
3EBV antibody categories: Low (#1:640), Medium/high (1:1280 to 1:20480).
doi:10.1371/journal.pone.0002505.t005
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of Burkitt lymphoma in Uganda, lending support to the view that
malaria prevention may impact on the incidence of this childhood
cancer [13]. However, it is important to note that our results were
based on a small subset of cases and controls and could be
explained by the effects of residual confounding by socio-economic
status. In Malawi, widespread distribution of subsidized bed nets
began in 2002, although the prevalence of use has been reported
to be higher in urban households compared to those in rural areas
[39]. No decline in the frequency of Burkitt lymphoma has yet
been reported.
In accordance with the Uganda case-control study [13], we also
found evidence to suggest that EBV and malaria act jointly as risk
factors for Burkitt lymphoma. Compared with those who had low
levels of both EBV and malaria antibodies, our data suggest that
children with high levels of both antibodies have 13 times the risk
of developing the tumor. While EBV viral load in blood has been
previously reported to be highest in children from malaria
endemic areas [40], the specific nature of the relationship between
EBV and malaria is unclear. Two hypotheses have been suggested
to explain this. First, malaria leads to reactivation and proliferation
of EBV latently infected B cells and second, that malaria may also
lead to suppression of EBV-specific T cell immunity, which allows
EBV to proliferate [41–43]. The apparently synergistic effect
suggests that infection with both EBV and malaria may be needed
to facilitate tumor formation.
That the odds of Burkitt lymphoma increased with the number
of children alive reported by mothers may be linked to exposure of
the index child to EBV infection and re-infection from other
family members [44,45]. Further, the odds of Burkitt lymphoma
increased significantly with increasing number of self-reported
maternal lifetime sexual partners and an association with high
EBV antibody titers in the mother was suggested. Although based
on small numbers, these findings may suggest that mothers of
Burkitt lymphoma cases are exposed to EBV (or perhaps multiple
strains of EBV) through sexual contact [46]. The mother may then
pass on EBV to the child, predisposing tumor development.
However, further analysis did not show any correlation between
number of self-reported lifetime sexual partners and levels of EBV
titers in the mother (results not shown), nor was there an
association between prevalence of maternal syphilis (as a marker of
sexual behavior) and risk of Burkitt lymphoma in the child.
Consequently, the significance of the findings relating to maternal
sexual and reproductive history is not clear.
It is possible that some case and control children might have
been misclassified, 75% of cases and 74% of controls had a
histological verification of diagnosis. This is a relatively high rate of
verification for an African series [16,47]. As described previously,
the jaw was the most common site for primary tumor presentation,
and the mean age at diagnosis was 7.1 years, also similar to other
studies [48,49].
In conclusion, this case-control study of Burkitt lymphoma
conducted among children in Malawi strengthens the evidence
associating the tumor with HIV, EBV and malaria. Improved
control of malaria, as well as the future development of EBV
vaccines [50] could play an important role in protecting African
children from this common and often fatal malignancy.
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